# NOS-IN-2

| | |
|---|---|
| **Cat. No.:** | HY-115916 |
| **CAS No.:** | 2766146-79-4 |
| **Molecular Formula:** | $C_{18}H_{20}F_3N_3O_2$ |
| **Molecular Weight:** | 367.37 |
| **Target:** | NO Synthase |
| **Pathway:** | Immunology/Inflammation |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |




## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | NOS-IN-2 (Compound 4i) is a potent, selective, imidamide derived NOS inhibitor with an $IC_{50}$ against iNOS of 20 μM, without inhibiting eNOS. NOS-IN-2 has little toxicity and can be used for studying inflammatory disorders[1]. |

| **$IC_{50}$ & Target** | iNOS | nNOS |
|---|---|---|
| | 20 μM ($IC_{50}$) | >1000 μM ($IC_{50}$) |

**In Vitro**

NOS-IN-2 (Compound 4i) shows high iNOS selectivity without eNOS inhibition activity [1].

NOS-IN-2 (0-100 μM, 30 min) has little toxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

| | |
|---|---|
| Cell Line: | HUVECs |
| Concentration: | 10, 20, 50, 100, 500 μM |
| Incubation Time: | 30 min |
| Result: | Had little toxicity, only at the concentration above 100 μM, the cell viability was significantly (approximately 20%) reduced. |

**In Vivo**

NOS-IN-2 (Compound 4i) is predicted to show oral bioavailability[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Fabio Arias, et al. Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors. Bioorg Med Chem. 2021 Aug 15;44:116294.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA